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Background: Chronic psychological stress and mental health disorders are endemic in
Western culture where population dietary insufficiencies of omega-3 fatty acids (n-3FA)
from seafood have been observed.
Objective: This study was designed to test for a causal relationship between one
of the most active components of fish oil, eicosapentaenoic acid (EPA), and chronic
psychological stress.
Method: A randomized double-blind, placebo-controlled clinical trial with
parallel-assignment to two groups was designed (Trial Id: ACTRN12610000404022).
The interventions were four EPA-rich fish oil capsules per day, delivering 2.2 g/d EPA (and
0.44 g/d DHA), or identical placebo (low-phenolic olive oil capsules with 5% fish oil to
aid blinding). The primary outcome was the between-group difference on the Perceived
Stress Scale (PSS-10) after 12 weeks supplementation. An a priori power analysis
determined that group sizes of 43 would provide 80% power to detect a significant
between-group difference of 12.5%, at α = 0.05. Ninety community members (64
females, 26 males) reporting chronic work stress were recruited via public advertising in
northern NSW, Australia.
Results: At baseline the omega-3 index (EPA + DHA as % to total fatty acids in
red blood cell membranes) was 5.2% in both groups (SD = 1.6% control group;
1.8% active group). After supplementation this remained stable at 5.3% (SD = 1.6%)
for the control group but increased to 8.9% (SD = 1.5%) for the active group,
demonstrating successful incorporation of EPA into cells. Intention-to-treat (ITT) analysis
found no significant between-group differences in PSS outcome scores post-intervention
(b = 1.21, p = 0.30) after adjusting for sex (b= 2.36, p= 0.079), baseline PSS (b= 0.42,
p = 0.001) and baseline logEPA [b = 1.41, p = 0.185; F (3,86) = 8.47, p < 0.01, n = 89,
R-square = 0.243].
Discussion: Treatment increased cell membrane EPA but, contrary to the hypothesis,
there was no effect on perceived stress. Limitations included an imbalance of gender
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in groups after randomization (68% of the males were in the placebo group). While we
found no significant interaction between sex and group on the outcome after adjusting for
baseline PSS, larger studies with groups stratified for gender may be required to further
confirm these findings.
Conclusion: This study demonstrated that 2. 2 g/day of EPA for 12 weeks did not
reduce chronic psychological stress.
Keywords: psychological stress, chronic stress, docosahexaenoic acid (DHA), omega-3 fatty acids,
eicosapentaenoic acid (EPA), fish oil, proinflammatory cytokines, coping
INTRODUCTION
Chronic psychological stress is prevalent in Australia and all
Western countries. Exposure to chronic psychological stress has
been linked to an increased risk of diseases. It doubles risk
of cardiovascular disease, depression and anxiety (LaMontagne
et al., 2006) and accelerates markers of aging, such as
decreased telomerase activity (Deng et al., 2016). Dietary (e.g.,
supplementation with omega-3 fatty acids and/or antioxidants)
and lifestyle (e.g., physical exercise, mindfulness practices) factors
are increasingly recognized as important mediators of resilience
to the damaging effects of chronic stress (Buchholz, 2015).
Psychological stress is mediated through limbic centers in
the brain, and involves a dynamic interplay between the
amygdala (brain region involved with fear/apprehension) and
the hippocampus (brain region involved with learning and
experience), with an executive regulation role for the prefrontal
cortex (cognitive appraisal). The biological stress response is
activated if the psychological appraisal of the threat results in
the perception that the demands will exceed the ability to cope
with those demands. Stress appraisal measurement is based on
the subjective evaluation of the stressor (primary appraisal) and
available coping resources (secondary appraisal; Lazarus and
Folkman, 1984). The net balance of these appraisals determines
the extent of physiological stress activation, if any (Rohrmann
et al., 1999; Ennis et al., 2001).
Physiological stress activation is mediated by the
hypothalamus-pituitary-adrenal (HPA) axis. The immediate,
acute response involves hypothalamic activation of sympathetic
nervous system and its activation of inflammatory pathways in
order to prepare the body for breaches to the skin and contain
blood loss and infection (Dhabhar, 1998). In acute situations
this is a survival mechanism, but long term this creates a
prothrombotic, proinflammatory physiology that itself becomes
stressful to the body if perpetuated (Gold, 2015). Cytokines
are messenger molecules that are produced by white blood
cells during stress. Overproduction of the proinflammatory
cytokines during stress stimulates the hypothalamus to continue
activation of the stress response (Elenkov and Chrousos, 2002).
Whether this is a healthy or dysfunctional effect depends upon
the situation. However, proinflammatory cytokines have been
demonstrated to prevent the HPA axis from efficiently returning
to homeostasis, leading to ongoing activation (Leonard, 2005).
HPA axis dysregulation has been associated with aging (Seeman
and Robbins, 1994) and stress- and mood-related disorders, such
as depression (Leonard and Song, 1996; Anisman and Merali,
2003).
Cortisol is the end product of HPA axis activation. It is an
anti-inflammatory fat-soluble steroid hormone that is released
by the adrenal gland during intense or prolonged stress. It is
adaptogenic, as it helps the organism to sustain its response to
ongoing stress by modulating the impact of the proinflammatory
stress mediators. However, sustained high levels of cortisol causes
neuronal damage in the hippocampus (Frodl and O’Keane,
2013), a brain region critical for higher order stress regulation.
Dehydroepiandrosterone (DHEA) is another steroid hormone
that is released alongside cortisol during stress. Its action is
antagonistic to cortisol and is known as the anti-stress hormone
(Hu et al., 2000; Bauer et al., 2013). The ratio between these two
hormones has been suggested as a marker of resilience to stress
(Yehuda et al., 2014).
Dietary omega-3 fatty acids (n-3FAs) have similar properties
to cortisol and also have adaptogenic effects (Hamazaki
et al., 2000; Bradbury et al., 2004); they are fat-soluble,
anti-inflammatory in nature and are known regulators of
proinflammatory cytokine production (Calder, 2006). In vitro
studies have shown that the n-3FAs eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) actively suppress IL-
6 production by human endothelial cells (De Caterina et al.,
1994; Khalfoun et al., 1997) and the production of IL-1, IL-6,
and TNF by human lymphocytes (Purasiri et al., 1997). Studies
have also established that dietary supplementation with EPA and
DHA suppresses IL-1, IL-6, and TNF production by monocytes
in rats (Foitzik et al., 2002). The addition of the omega-3 rich
flaxseed oil to domestic food products was shown to reduce
proinflammatory cytokine production in humans (James et al.,
2000). A significantly higher proinflammatory response to stress
during exams was demonstrated in medical students who had
lower baseline levels of n-3FAs (Maes et al., 2000).
In addition to their anti-inflammatory effects in the immune
system, n-3FAs seem to have protective effects on stress-related
brain regions. In animal studies EPA was demonstrated to be
neuroprotective in the hippocampus against stress-induced cell
death in rats. The mechanism appeared to involved upregulation
of IL-10 (Lynch et al., 2004). To mimic a stress response,
lipopolysaccharide (LPS) is used to induce proinflammatory
IL-1β levels in the hippocampus, through upregulation in
the expression of the IL-1 receptor Type I protein (IL-1RI).
Increased IL-1RI activates a cascade of pathways resulting in
neuronal cell death and consequential interference in long-term
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potentiation (involved with the laying down of new memories).
However, these LPS-induced changes were prevented with the
administration of the regulatory cytokine IL-10 (Lynch et al.,
2004). This suggests the potential for an active role of stress
regulation by IL-10 at the hippocampal level.
EPA was shown to enhance hippocampal IL-10 levels, which
were inversely correlated with IL-1β (Lynch et al., 2003). In
a study involving whole body exposure to irradiation in rats,
IL1β levels were increased in the hippocampus, which activated
the cascade of events leading to cell death and interference of
long-term potentiation. However, rats that were given EPA prior
to exposure were completely spared the radiation-induced cell
death in the hippocampus, and did not exhibit interruptions in
long-term potentiation. This suggests the potential for an active
role for EPA in stress regulation.
Most Australians are failing to meet the minimum intake
requirement for the long chain omega-3 fatty acids. The National
Health and Medical Research Centre (NHMRC) established
Suggested Dietary Targets (SDT) for the long chain omega-
3 fatty acids at 610mg/d for men and 430mg/d for women
to reduce chronic disease risk (NHMRC 2006). In 2006, the
Australian median daily intake was only 121mg/d (Meyer
et al., 2003; Howe et al., 2006; Meyer, 2011). This indicates
that most Australians are consuming about one quarter of the
recommended daily requirements of these essential nutrients.
This remained unchanged when 2011-2012 Australian data was
analyzed (Meyer, 2016). This is concerning given that Hibbeln
(Hibbeln, 1998) demonstrated that fish consumption per capita
was inversely correlated with the annual prevalence of major
depression per country.
If n-3FAs regulate cytokine production during chronic stress,
then intervention with dietary n-3FAs may reduce stress-related
susceptibility to disease. To test this theory, this study aimed to
demonstrate whether dietary supplementation with an EPA-rich
fish oil can alleviate perceived stress in people with chronic stress
compared with a placebo. Chronic work stress was used as a
relatively stable model of stress in human participants. As it was
postulated that EPA is the n-3FAmost likely to have an impact on
inflammatory mediators, an EPA-rich fish oil was chosen as the
predominant fish oil component for the active intervention. The




The study was designed as a randomized, placebo-controlled,
double-blind, parallel-assignment clinical trial. The two
intervention groups for comparison were the active fish oil (FO)
group and the placebo control group, as shown in Figure 1.
The study design was registered prospectively at the Australian
Clinical Trials Register (Trial Id: ACTRN12610000404022).
Study Protocol
Participants were required to attend the sampling clinic on two
occasions, baseline and post-intervention, for about an hour. All
clinics were conducted between 7 and 10 a.m. Participants were
FIGURE 1 | Design of RCT.
required to fast from all food and beverage (except for water),
and to refrain from over-the-counter medications and heavy
physical exercise for the 12 h prior to the clinic. Questionnaires
were administered, and blood and saliva samples were collected
at baseline, then again after 12 weeks of supplementation.
Trained clinicians conducted a clinical interview and full physical
examination of participants on each occasion; including height,
weight, body mass index, waist circumference, blood pressure,
and heart rate.
In addition to the sampling clinics, participants were required
to attend a “bottle exchange” clinic once per month to return the
current bottle with whatever capsules remained and to collect a
new bottle containing a month’s supply.
Outside the clinics every 2 weeks during the study the PSS
questionnaire was emailed to participants to complete and return
within 72 h to monitor the stress levels during the study.
Outcome Measures
The primary outcome measure was the difference between the
fish oil group and placebo group in mean changes over time
on the ten-item Perceived Stress Scale (PSS). The secondary
outcomemeasures were the differences between the fish oil group
and placebo group in mean changes over time in (i) plasma
concentrations of IL-1β, IL-6, TNF-α, and IL-10 (ii) salivary
cortisol/DHEA ratio, (iii) Depression, Anxiety, Stress Scale
(DASS), (iv) Occupational Stress Inventory (OSI) Strain and
Resources subscales, (v) COPE Inventory, and (vi) Copenhagen
Burnout Inventory.
Study Population
This study was carried out in accordance with the Australian
Government’s National Statement on Ethical Conduct in
Human Research (2007)—Updated May 2015. The protocol was
approved by the Southern Cross University Human Research
Ethics Committee. Paid advertisements and media coverage in
regional papers and radio stations advertised that the study was
particularly targeting people with moderate to high levels of work
stress. Volunteers who met the study criteria were randomized
into one of two groups.
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Randomization, Concealment, and Blinding
An independent staff member not associated with the current
study or funding bodies, conducted the randomization and
coding of the supplement bottles. A computer program was used
to generate the randomization schedule. The coding was kept
in sealed, opaque envelopes in a locked filing cabinet by this
staff member until the completion of the trial. The participants,
data collection clinicians, researchers, laboratory and statistical
analyses were all blinded to the allocation to groups throughout
the study. Blinding was aided by the addition of 5% fish oil to the
placebo capsules by the manufacturer. The placebo capsules were
identical to the EPA capsules in size, shape, color, smell and taste.
Sample Size Determination
In our previous pilot randomized controlled intervention study
(Bradbury et al., 2004), our sample of 30 participants with chronic
work stress obtained a mean baseline score of PSS = 24 and a
26.7% [6.4 (±5.8)] mean reduction from baseline to completion
with treatment with fish oil (FO) and a 12.5% [3.0 (±4.8)]
mean reduction with placebo. A power analysis based on these
parameters determined that equal group sizes of n = 43 would
provide at least 80% power to detect a significant difference
between groups, assuming a reduction of 25% [6.0 (±6.0)] for
the fish oil group and a reduction of 12.5% [3.0 (±5.0)] for the
placebo, controlling alpha at 0.05 for a one-tailed test. In case we
observed a 30% drop out rate, as occurred in the pilot study, we
aimed to recruit 55 subjects in each of the two groups to allow
for a fully powered per-protocol hypothesis test, secondary to the
intention-to-treat (ITT) analysis. Hence, it was anticipated that
n = 110 would provide the study with the best chance of finding
a significant difference between the groups if one exists in the
population of people with chronic psychological stress.
Study Criteria
Participants were included in the study if they reported
experiencing chronic work stress and if they obtained moderate
to high stress scores (PSS ≥ 17); they reported having not
taken a course of fish oil within the past 3 months, and/or that
they consumed less than two non-fried fish meals per week on
average; and that they were willing to refrain from non-steroidal
anti-inflammatory drugs, aspirin, and other complementary
medicine supplements for the trial duration. Participants were
excluded from the study if they were taking immunosuppressive
medications; or had any systemic inflammatory disorder; a
current infection; unexplained weight loss; malignancy; or any
significant disease or disorder or any condition that, in the
opinion of the investigators, might interfere with the study
objectives.
Study Medication
Eicosapentaenoic acid (EPA) from fish oil constituted the
active intervention. Each capsule contained 1,000mg fish oil,
comprising 660mgmarine triglycerides as EPA 550mg and DHA
110mg. Four capsules per day delivered 2.2 g EPA, and 0.44 g
DHA. This equated to a total of 2.64 g per day of the long chain
omega-3 fatty acids. The placebo capsules, contained 950mg low-
phenolic olive oil, consisting predominately of monounsaturated
fatty acids, and 50mg fish oil (5%) to assist with blinding. The
intervention involved participants taking four capsules per day,
two with breakfast and two with dinner. All bottles with any
remaining supplements were collected to determine how many
capsules remained as a measure of compliance.
Measurement Instruments
PSS-10
The PSS (Cohen et al., 1983) is a validated and reliable subjective
measure of the amount of psychological stress an individual
perceives. The questions ask respondents about thoughts and
feelings they have experienced during the last month. Items are
answered in a Likert fashion from “never” = 0 to “very often”
= 4. Scoring of the PSS involves summing across the 10 items,
resulting in a single score in the range from 0 to 40. Higher scores
reflects higher perceived stress.
Membrane Fatty Acids
Venous samples were collected in 4mL EDTA tubes, which were
gently inverted at the time of collection. Upon arrival at the
lab (Centre for Phytochemistry & Pharmacology at Southern
Cross University), the tubes were centrifuged for 5min at 2,000 g
(3,057 rpm) at room temperature (25◦C). The plasma was
separated from the packed red cells at the bottom of the tube,
leaving ∼2ml of plasma and 2ml of red blood cells (RBC). The
plasma and the buffy coat were transferred by pipette out of
the tubes. The packed red cells at the bottom of the tube were
transferred into Eppendorf tubes and stored at −80◦C. At the
end of the data collection period, they were transported as a
batch on dry ice to the University of Wollongong for fatty acid
analysis. RBC Fatty Acid Analysis (FAA) was conducted using
the protocol previously published by Lepage and Roy (1986).
Through comparison with known fatty acid standards, individual
fatty acids were identified. The standards used were from Supelco
FAME mix C4-C24 analytical standard (Product #18919-1 AMP,
Sigma-Aldrich, Castel Hill, Australia).
Proinflammatory Cytokines
EDTA tubes were used to collect 5ml of plasma for the cytokines,
while 5ml blood was collected in serum separation tubes for
the analysis of serum C-reactive protein concentration. Samples
were transported directly to the Centre for Phytochemistry &
Pharmacology at Southern Cross University, where the plasma
was centrifuged for 10min at 4◦C at 2,500 rpm. Serum was
similarly centrifuged after it had been separated for 10min
at room temperature. The plasma and serum were divided
into 500ml aliquots, stored in Eppendorf tubes and frozen at
−80◦C. At the end of data collection, samples were transferred
in one batch on dry ice to the University of Queensland.
Plasma samples were analyzed in single using ELISA kits
for IL-1β, IL-6, and TNF-α (Quantikine HS R©, RnD Systems,
Minneapolis, MN) and IL-10 (Quantikine R©, RnD Systems)
according to the manufacturer’s instructions. Serum samples
were analyzed in single for high-sensitivity C-reactive protein
using a commercial kit (Kamiya Biomedical, Seattle, WA)
according to the manufacturer’s instructions and an automated
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spectrophotometer (Cobas MIRA, Roche Diagnostics, Basel,
Switzerland).
Salivary Cortisol/DHEA Ratio
During the data collection clinics and prior to blood analysis,
saliva was collected in 1.5ml conical microtubes (Quality
Scientific Plastics, Petaluma, California), which were transferred
in a transportable insulated box from the clinic to the laboratory
to be stored in a −20◦C freezer until the samples from the
complete study had been collected. They were then transferred
as a batch to the −80◦C laboratory freezer where they were
stored until they were thawed for analysis. Saliva was collected
using a small plastic 6 cm straw, according to the “passive drool”
collection. Briefly the participants were asked to allow saliva
to run into the straw provided for collection into the tube,
which was held directly under the mouth. Immediately prior to
collection, participants were asked to rinse out their mouth with
water and then to sit comfortably and wait for saliva that was
naturally accumulating in the mouth to drip through the straw
into the tube. Salivary cortisol and DHEA were, respectively,
analyzed using the manufacturer’s instructions with standard
salivary ELISA kits (IBL, Australia).
The Depression, Anxiety, Stress Scale (DASS-21)
The brief (21-item) DASS (Lovibond and Lovibond, 1995) is
a validated and reliable subjective measure of three constructs;
stress, anxiety and depression. There are seven questions
pertaining to each construct. The items for each construct are
summed, giving a total score for each subscale. Subscale scores
range between 0 and 21.
The Occupational Stress Inventory- Revised (OSI-R)
The OSI-R (Osipow, 1981) is a multidimensional measure of
occupational stress. It is a self-report instrument involving three
questionnaires. There are six subscales in the Occupational
Roles Questionnaire (ORQ), four subscales in the Psychological
Strain Questionnaire (PSQ) and four subscales in the Personal
Resources Questionnaire (PRQ). Each scale consists of several
subscales. Each subscale consists of 10 items. Each item is
answered in a five point Likert response ranging from “rarely
or never” to “most of the time.” Reliability Chronbach alpha
coefficients were demonstrated to range from 0.7 to 0.89 among
the subscales, and 0.88 for the ORQ, 0.93 for the PSQ and 0.89
for the PRQ. Only the Strain and Resources subscales were used
in this study.
The COPE Inventory
The COPE (Carver et al., 1989) is a reliable and validatedmeasure
of coping styles. It consists of 15 subscales, addressing both
positive (such as use of humor) and negative (such as denial)
coping mechanisms. Items are measured on a four-point Likert
scale from 1 = “I haven’t been doing this at all” to 4 = “I have
been doing this a lot.” The scores on each subscale range between
4 and 16. The COPE is a most widely used measure of coping
due to its derivation from theory and its standardized scoring
procedure.
Burnout
Burnout is a prolonged physical and psychological exhaustion,
that has been associated with chronic work stress (Maslach et al.,
2001). In order to control for this as a potential covariate, the
Copenhagen Burnout Inventory (Kristensen et al., 2005) was
included.
Statistical Analysis
Red blood cell membrane EPA (mEPA) was assessed at baseline
in both groups as the most significant potential covariate. Pre-
treatment levels would be included in the statistical model
should the groups differ at baseline. The success of the
random assignment to groups would be further tested in
terms of age, gender and other potential covariates, which
would also be included were they to differ between groups
at baseline. ITT analysis was used for the primary analysis,
incorporating a general linear model to adjust for baseline stress
levels and covariates, where required. Probability levels ≤0.05
was considered significant for the primary analysis, secondary
analyses would be treated as exploratory. Statistical analyses were
conducted using Stata v13.
RESULTS
Participants
Ninety participants (n = 90, 64 female and 26 male) were
randomized. Figure 2 shows the flow of participants through
the study. During the 3 months of the supplementation
period, 15 participants (2 male and 13 female) withdrew for
various personal or medical reasons. Most were unrelated to
the intervention, but there were issues of compliance with
the protocol, particularly of continuing to take the fish oil
supplement and abstain from taking other supplements. One
withdrawal was reportedly associated with an adverse reaction of
mild abdominal bloating attributed to the intervention. However,
no withdrawal-retest was conducted to demonstrate whether the
intervention caused the symptom.
Baseline Characteristics
Baseline demographic and clinical characteristics were fairly
evenly distributed between the groups as shown in Table 1.
However, there was a lower proportion of males allocated to
the active (fish oil) group compared with the placebo control
group (68 vs. 32%). In addition, a higher proportion of people
experiencing financial stress (69 vs. 31%) and a significant trauma
in the 6 months prior to the study were allocated to the active fish
oil group (70 vs. 30%).
Descriptive Statistics
The group means and standard deviations at baseline (pre) and
at post-intervention (post) for the serum fatty acids are given in
Table 2. There were no significant differences between the groups
at baseline for any of the fatty acids, while there were significant
differences in the fatty acids at Time 2. The main differences
were a dramatic increase in the EPA content of RBC membranes,
in both absolute levels (µg/ml) and as a percentage of total
fatty acids(%), with a corresponding decrease in arachidonic acid
Frontiers in Pharmacology | www.frontiersin.org 5 October 2017 | Volume 8 | Article 551
Bradbury et al. EPA in Stress
FIGURE 2 | Flow of participants through the study.
levels for the fish oil group compared with controls. The pre and
post group means for the secondary outcomes are provided in
Table 3.
Primary Outcome
An ITT analysis was conducted for the difference between groups
at the post-intervention point for the primary outcome, the PSS.
As the PSS had been administered every 2 weeks during the study
(see Figure 3), the last observed value for the PSS was brought
forward and used in the post-intervention (Time 2) analysis (n
= 90). That is, there were n = 75 participants in week 12, but
by using the last known PSS for the participants who withdrew,
the Time 2 analysis was conducted on all participants who were
randomized (n= 90).
At baseline, the total scores on the PSS-10 were mean (M =
21.68; SD = 4.43) for the placebo group and M = 22.93 (SD
= 5.18) for the active group (Figure 3). Both groups steadily
declined in stress levels, with the placebo group declining more
than the active group at the week 12 mark (Figure 3). When
the last values were bought forward, the post-intervention stress
scores were M = 16.07 (SD = 6.28) for the placebo control and
M = 18.36 (SD = 5.39) for the active group, which was not a
significant between-group difference (t = 1.86, p= 0.07).
Sex, financial stress and significant trauma in the 6 months
prior to the study were checked at baseline. Sex was found to
be a significant cofactor, with the mean PSS for males (M =
20.56, SD = 5.69) lower than for females (M = 22.98, SD =
4.32; t = −2.18, p = 0.03) at baseline and post-intervention
males (M = 14.32, SD = 5.28) vs. females (M = 18.32, SD =
5.83; t = −2.99, p = 0.004). Because sex was not balanced after
randomization, an interaction term for sex∗group was modeled,
but was non-significant and therefore not included in the final
model.
There was also a potential imbalance in the variance in
absolute levels of membrane EPA (µg/mL). At baseline,
the fish oil group had a mean EPA of 6.1µg/mL (SD
= 10.2µg/mL) where the control group had 4.3 (4.9)
µg/mL (Table 2). The distribution was highly positively
skewed in both groups. The natural log of EPA (lnEPA)
as a percentage to total fatty acids was taken as the best
marker for membrane EPA, with notable improvement in its
distribution.
While there were no between-group differences in lnEPA,
there was a trend toward sex differences, with females trending
higher than males (mean difference 0.21, p = 0.099). The
interaction with sex and EPA was modeled with the outcome
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TABLE 1 | Baseline demographic and clinical characteristics for the two groups goes here.
Active treatment group (N = 45) Placebo control group (N = 45)
Mean (Standard Deviation) Mean (Standard Deviation)
Age (years) 43.24 (9.52) 45.38 (9.17)
Sex Female 37 (56.9%) 28 (43.1%)
Male 8 (32.0%) 17 (68.0%)
Body Mass Index 25.3 (4.9) 26.4 (5.0)
Waist circumference (cm) 65.8 (33.5) 62.1 (38.0)
Heart rate (beats per min) 67.3 (11.2) 67.1 (11.2)
Blood pressure (mm Hg) Systolic 126.4 (16.3) 126.9 (15.3)
Diastolic 78.8 (11.3) 78.6 (11.4)
Number (percentage) Number (percentage)
Primary carer status Child, elderly, disable person 21 (53.8) 18 (46.2)
Relationship status Single 7 (63.6) 4 (36.4)
Widowed/divorced 30 (57.1) 22 (42.9)
Married 31 (45.6) 37 (54.4)
Recent loss 2 (66.7) 1 (33.3)
Ethnicity White Caucasian 43 (48.9) 45 (51.1)
Aboriginal/Torres St Is 1 (100) 0 (0)
Other 1 (100) 0 (0)
Occupation status Manager 9 (40.9) 13 (59.1)
Professional 17 (50) 17 (50)
Associate professional 12 (75) 4 (25)
Trades 0 (0) 3 (100)
Advanced clerical/service 3 (42.9) 4 (57.1)
Sales and service 0 (0) 3 (100)
Elementary clerical, sales, service 2 (100) 0 (0)
Labourer 1 (50) 1 (50)
Financial Stress Unable to raise $2,000 18 (69.2) 8 (30.8)
Significant trauma Within 6 months 16 (69.6) 7 (30.4)
but found to be non-significant when two influential cases
were removed. Baseline EPA was not a significant covariate
in the model but was nevertheless retained as it was part of
the a priori study design to control for subtle differences at
baseline.
In the final model, ITT analysis found no significant between-
group differences in PSS outcome scores post-intervention (b =
1.21, p = 0.30) after adjusting for sex (b = 2.36, p = 0.079),
baseline PSS (b = 0.42, p = 0.001) and baseline lnEPA [b = 1.41,
p = 0.185; F(3,86) = 8.47, p < 0.01, n = 89, R-square = 0.243]
(Table 4).
Compliance
Ameasure of compliance was obtained for 77% of the sample. Of
these, 73% were compliant at the 85% level or higher. There were
no differences between the groups or genders for compliance.
Cortisol:DHEA Ratio
The cortisol:DHEA ratio post-intervention was not influenced
by treatment group (Table 5). However, there were strong trends
toward significant effects and of sex (p= 0.07) and age (p= 0.06)
on the ratio of cortisol to DHEA. The model in Table 5 shows
that this ratio increased as age increased, and also that the ratio is
increased for females.
Cytokines
There were no significant treatment effects on any of the
cytokines or CRP. However, the PSS at time 2 was a significant
predictor of both IL-6 (beta = 0.04, t = 2.75, p = 0.01) and
CRP (beta = 0.03, t = 2.04, p = 0.05) controlling for the
respective baseline measures. PSS at time 2 was also an inverse
predictor of IL-10, after controlling for baseline IL-10, although
not significantly (beta=−0.03, t =−1.32, p= 0.19).
Frontiers in Pharmacology | www.frontiersin.org 7 October 2017 | Volume 8 | Article 551
Bradbury et al. EPA in Stress
TABLE 2 | Group means and standard deviations at baseline (pre) and at post-intervention (post) for the membrane and serum fatty acids.
















Arachidonic acid 59.0 (26.3) 56.5 (27.5) 36.4 (10.2) 45.0 (12.4) −8.7 3.29 0.002*
EPA 6.1 (10.2) 4.3 (4.9) 13.4 (7.5) 3.8 (3.3) 9.6 −7.06 <0.001*
DHA 19.1 (9.1) 19.5 (11.1) 16.9 (1.4) 15.0 (5.4) 1.9 −1.59 0.117
PERCENTAGE (%) OF TOTAL FATS
Arachidonic acid 13.3 (1.4) 13.2 (1.2) 10.9 (1.1) 13.2 (1.2) −2.3 8.69 <0.001*
EPA 1.2 (1.4) 1.0 (1.0) 4.1 (1.2) 1.2 (1.3) 2.9 −10.05 <0.001*
DHA 4.0 (0.9) 4.2 (1.4) 4.8 (0.7) 4.1 (1.0) 0.7 −3.51 0.001*
EPA + DHA (%) 5.2 (1.6) 5.2 (1.8) 8.9 (1.5) 5.3 (1.6) 3.6 −10.35 <0.001*
AA:EPA (%) 16.5 (8.6) 16.8 (6.7) 3.0 (1.2) 16.0 (6.9) −13.0 11.46 <0.001*
EPA:AA (%) 0.10 (0.16) 0.08 (0.10) 0.38 (0.15) 0.10 (0.11) 3.00 9.10 <0.001*
Diff, mean (Active group)—mean (Placebo group) at post-intervention; EPA + DHA is known as the “omega-3 index.”
TABLE 3 | Baseline and Post intervention group means and standard deviations for secondary outcomes.
Baseline (Pre-intervention) Time 2 (Post-intervention)
Salivary biomarkers (nmol/L) Fish oil group (N = 40) Placebo (N = 39) Fish oil group (N = 38) Placebo (N = 36)
Cortisol 12.65 (7.29) 13.62 (8.93) 15.95 (8.11) 13.40 (7.22)
DHEA 0.97 (0.65) 1.24 (0.94) 1.22 (1.03) 1.48 (1.86)
Cortisol:DHEA 16.98 (11.48) 14.43 (10.37) 19.12 (13.39) 15.57 (11.87)
Serum inflammatory markers Fish oil group (N = 45) Placebo (N = 44) Fish oil group (N = 36) Placebo (N = 36)
TNF pg/ml 0.97 (0.65) 0.93 (0.48) 1.23 (1.0) 1.07 (0.67)
IL-6 pg/ml 0.90 (0.81) 0.95 (0.74) 0.91 (0.69) 1.00 (0.97)
IL-10 pg/ml 2.6 (1.150) 2.12 (0.99) 2.15 (1.22) 2.01 (0.93)
CRP mg/l 1.33 (1.49) 1.19 (1.48) 1.18 (1.38) 0.84 (0.96)
Psychological self-report scales Fish oil group (N = 40) Placebo (N = 44) Fish oil group (N = 29) Placebo (N = 29)
OSI Roles 158.2 (26.7) 155.8 (27.8) 149.9 (27.1) 145.8 (21.5)
OSI Strain 109.8 (21.4) 107.8 (23.2) 92.4 (17.2) 90.5 (21.2)
OSI Resources 110.3 (20.4) 111.6 (19.5) 114.9 (19.1) 116.9 (18.1)
DASS Stress 19.3 (9.6) 19.5 (9.0) 14.7 (7.8) 15.3 (8.4)
DASS Anxiety 9.7 (8.4) 9.32 (9.5) 6.2 (6.3) 7.0 (8.6)
DASS Depression 15.6 (10.8) 12.7 (10.8) 10.9 (8.9) 12.2 (10.7)
COPE Active 10.2 (2.5) 10.5 (1.5) 10.2 (2.4) 10.7 (2.6)
COPE Denial 6.0 (2.0) 6.2 (2.0) 5.3 (2.1) 5.9 (2.2)
COPE Disengagement 7.4 (2.3) 6.2 (2.0) 6.6 (1.9) 6.2 (1.9)
Burnout 58.0 (16.7) 58.0 (16.8) 56.2 (19.5) 50.0 (20.0)
DASS
The group means for the DASS subscales are
given in Table 3. The DASS subscales correlated
with each other and the other stress measures, the
stress subscale is shown in Table 6. There were no
significant treatment effects on any of the DASS
subscales.
OSI (Occupational Stress Inventory)
The group means for the OSI-R subscales are given in Table 3.
The OSI-R subscales correlated with each other and the other
stress measures, shown in Table 6. There was no effect for group
on the OSI subscales; the Occupational Roles Questionnaire
(ORQ), the Personal Strain Questionnaire (PSQ) nor the
Personal Resources Questionnaire (PRQ).
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Burnout
There was no difference between the groups at baseline for
burnout, thus it was not included in the modeling as a covariate
(Table 3).
COPE Denial
Group means for COPE Denial, COPE Active and COPE
Disengagement are included in Table 3. In a general linear model
of each of the 15 subscales of the COPE Inventory, only one
subscale had significant effects for treatment group after baseline
levels were taken into account. This was for the subscale, Denial.
This subscale contained four items that asked questions such
as: “I pretend that it hasn’t really happened.” Sex was not a
significant covariate in this model, so was not included. The sign
of the coefficient is negative, indicating that scores on denial are
lower for the active (EPA) group [indicator coding for group was
0= placebo, 1= active; F(3, 56) = 16.94, beta=−1.17, t=−2.58,
p= 0.013, 95% CI:−2.08,−0.26].
At post-intervention, Denial was correlated with IL6 (0.21,
p = 0.116) and negatively correlated with EPA (r = −0.18, p =
0.177), although neither correlations were statistically significant
in this sample size (n = 58). Denial was significantly correlated
with the PSS (r = 0.38, p = 0.003), DASS Stress (r = 0.29, p =
0.027), DASS Anxiety (0.34, p = 0.008), DASS Depression (r =
0.46, p= 0.0003), OSI Psychological Strain (r = 0.30, p= 0.021),
OSI Interpersonal Strain (r = 0.33, p = 0.012), OSI Physical
Strain (0.44, p = 0.0005). It was not related to OSI Vocational
Strain (0.044, p= 0.74).
Blinding
To assess the success of the blinding, each participant was asked
at the end of the study to indicate the supplement they believed
they were taking during the trial. The available options were the
active and placebo (fish oil and olive oil, respectively) and three
other options (corn oil, linseed oil, or other oil). Interestingly,
almost half of the fish oil group (18/37, 47%) correctly identified
fish oil, while almost one-third of the placebo group incorrectly
nominated fish oil (12/38, 32%) as the group to which they had
been allocated. Conversely, only 4 (11%) from the placebo group
correctly identified olive oil as the agent, where 3 (8%) from the
fish oil group incorrectly identified olive oil.
DISCUSSION
This study found that there was no significant treatment effect
for EPA on the Perceived Stress Scale (PSS-10) scores after 12
weeks of dietary supplementation in people with chronic work
stress. ITT analysis was used, which included all participants
who started the study. The 15 participants who withdrew
were included by bringing their last PSS score forward. In
some cases, the baseline score was used as the outcome score,
potentially underestimating the true differences. However, in a
sensitivity analysis, the effect of treatment group was similarly
non-significant when only those who completed the study were
included, after controlling for baseline stress and EPA and sex.
Baseline EPA was included in the modeling as it was specified
from the outset to be highly variable in the population; and
FIGURE 3 | PSS group means during the trial, with 95% confidence intervals.
Baseline n = 90, week 2 n = 65, week 4 n = 70, week 6 n = 63, week 8 n =
52, week 10 n = 62, week 12 n = 75.
TABLE 4 | Coefficient table for the effect of treatment group on PSS at
post-intervention (n = 90).
PSS-post Coef. Std. Err. t P [95% Confidence
Interval]
Group 1.21 1.16 1.04 0.302 −1.10 3.52
Sex 2.36 1.33 1.78 0.079 −0.28 5.00
PSS-baseline 0.42 0.12 3.52 0.001* 0.18 0.66
logEPA-baseline 1.41 1.05 1.34 0.185 −0.69 3.51
_cons 5.58 2.72 2.05 0.043 0.17 10.98
Indicator variables coding: Group: 0 = placebo, 1 = active; Sex: 0 = male, 1 = female;
*Denotes significance; logEPA-baseline is the log of the baseline EPA (% of total fatty
acids). The log was taken to comply with ITT (analyses all cases) and model assumptions
(linear relationship with outcome), as there were a few extreme high values for each group
that created a strong skew for untransformed EPA, as % to total fatty acids; The values
for PSS-post for the participants who withdrew (n= 15) were the last PSS score available
bought forward to allow intention to treat analysis (see also Figure 3).
indeed this variability was found in this sample, particularly for
the active group.
The objective of this modeling was to assess the impact of
treatment group on PSS scores after adjustment for baseline
scores and significant covariates. The result was that the
hypothesis that there would be a significant difference between
the treatment groups at completion was not supported. However,
the final model only accounted for approximately one-quarter
(24%) of the variance in the outcome, perceived stress. This
strongly suggests that there may be other significant factors that
are omitted from this modeling. Hence, this result should be
interpreted within the context of hypothesis testing and not as
predictive model for stress in the population. Further exploratory
modeling may explain more of the variance in the outcome to
give a more complete understanding of the factors that influence
stress outcomes, including a potential role for essential fatty
acids, beyond the constraints of an ITT between-group difference
hypothesis test.
Both groups experienced reductions in stress over time. This
had been anticipated due to the regression-to-the-mean effect.
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TABLE 5 | Coefficient table for the effect of treatment group on Cortisol:DHEA
ratio (n = 75).
Cortisol:dhea
post
Coef. Std. Err. t p [95% Confidence
Interval]
Group −1.51 2.31 −0.66 0.514 −6.11 3.09
Sex 4.79 2.55 1.87 0.065 −0.31 9.88
Age 0.24 0.12 1.94 0.056 −0.01 0.49
Cortisol:dhea pre 0.61 0.11 5.63 <0.001** 0.39 0.83
Constant −7.17 5.73 −1.25 0.215 −18.60 4.26
Dummy variables coding: Group: 0 = placebo, 1 = active; Sex: 0 = male, 1 = female;
**Denotes significance at the p = 0.01 level.
TABLE 6 | Correlation matrix for the various stress measures and IL-6 at time 2.






n 57 59 59
OSI-Strain 0.246 0.734 0.726
p-value 0.068 <0.001** <0.001**
n 56 58 58 58
OSI-Resources −0.009 −0.405 −0.203 −0.450
p-value 0.945 0.002** 0.123 <0.001**
n 57 59 59 58
*p is significant at the 0.05 level; **p is significant at the 0.01 level; IL-6 is interleukin-
6; DASS-Stress is the stress subscale of the Depression and Anxiety Scale; OSI-R
Occupational Stress Inventory-Revised; OSI-Strain is the Personal Strain Questionnaire
(PSQ) subscale of the OSI-R; OSI-Resources is the Personal Resources Questionnaire
(PRQ) subscale of the OSI-R.
The study recruitment had called for people with high work
stress that had been ongoing for at least 3 months, so the scores
were likely to fall. In our previous pilot study, we had shown a
trend toward an enhanced reduction in stress in an active group
taking a DHA-rich fish oil supplement (Bradbury et al., 2004).
By conducting an a priori power analysis for the current trial,
based the pilot study, the current trial was adequately powered to
assess whether an EPA-rich fish oil supplement could significantly
reduce stress over time in a sample from the population of people
with chronic work stress.
There were some interesting sex differences on the stress
outcomes in the current study. It was concerning that the random
allocation to groups resulted in a lower proportion of males in
the active fish oil group, while the ratio of males to females in
the placebo group was relatively balanced.Males had significantly
lower unadjusted stress scores than females at both time points.
However, after adjusting for baseline PSS and baseline EPA levels,
the effects of sex on the PSS scores at post-intervention were
non-significant. Nevertheless sex was included as a covariate in
all modeling to control statistically for the post-randomization
imbalance between the groups. Experimental control through
stratified allocation to larger groups should be considered in
future studies using stress and coping as outcomes. Similarly, the
pooling of data frommultiple trials into a meta-analysis may help
to control for the imbalance in the current study.
Another source of imbalance in the data was observed in the
testing for agent identification at the end of the trial. Almost half
(47%) of the fish oil group correctly identified fish oil, but only
11% of the placebo group correctly identified olive oil. Indeed,
almost one-third (32%) of the placebo group believed themselves
to have been allocated to the active fish oil group. This belief of
by a substantial cohort of the control group has the potential
to enhance the so-called “placebo effect,” which could under-
estimate a true between-group difference, should one exist. This
is a rigorous aspect of the experimental design which errs on the
conservative side, giving rise to a preference for a type II error
(failure to reject the null hypothesis) over a type I error (wrongly
rejecting the null hypothesis). There had been 5% fish oil added
to the placebo supplements to aid the blinding, which clearly
worked as a successful masking strategy.
There were no effects for treatment group across any of the
stress measures included as secondary outcomes in this study.
While there was one significant effect found for EPA among the
coping measures (the Denial subscale of the COPE inventory),
it must be emphasized that this study was not designed to
test conclusively for secondary outcomes. The significance level
was not adjusted for multiple tests and there had been no a
priori power analysis for secondary outcomes, so the findings on
secondary outcomes must be interpreted as exploratory. As such,
a range of secondary outcomes were included to enable such
exploratory analyses for potential mechanisms and to suggest
areas for future research.
Denial is considered a maladaptive coping mechanism, along
with others such as disengagement. High levels of denial
have been shown to predict worse outcomes for anxiety after
cognitive behavior therapy (Oei et al., 2013). The current study
finding that the EPA group had lower levels of denial than
the placebo control group is consistent with modeling studies
demonstrating an effect for omega-3 fatty acids on coping and
resilience outcomes (Bradbury et al., 2012; Yoshikawa et al.,
2015). While modeling was conducted with cross sectional data,
and was therefore not designed to demonstrate causality, the
current finding contributes to the mounting body of evidence
suggesting a potential adaptogenic role for dietary omega-3 fatty
acids.
There has been much interest in the inflammatory impact
of stress in mental health disorders, and the potential of the
omega-3 fatty acids to ameliorate this (McNamara, 2015). The
current study found that interleukin 6 (IL-6) was correlated
with all three stress measures (PSS, DASS-Stress, OSI-Strain).
However, there was no direct correlation between the omega-
3 fatty acids and stress or inflammatory measures. This finding
is not consistent with Maes et al. (2000) who demonstrated
that a membrane omega-3 fatty acids at baseline predicted
proinflammatory cytokine changes during exam stress. It could
be argued, however, that exam stress is a different form of
stress, perhaps more acute and self-limiting, and not consistent
with the type of chronic stress one encounters in the work
place.
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Exposure to ongoing work pressures could result in
physiological adaptations; perhaps proinflammatory mediators,
while initially raised, had subsided over time. Perhaps there
was no correlation between the omega-3 fatty acids and the
proinflammatory cytokines in the current study because the
cytokines and C-reactive protein were not significantly elevated.
A systematic review (Johnson et al., 2013) of work stress and
C-reactive protein (CRP) reported on six studies that had
examined the relationship, but only half found a significant
relationship between work stress and CRP and the other half
did not. Many of those analyses were subgroup analyses,
secondary to the purpose of data collection. One of which
used data from the Whitehall study, the large cohort of civil
servants in the UK, which found the correlation was not
significant.
By design, the chosen study intervention was high in EPA
(83.3%) but low in DHA (16.6%). The decision to test for one and
not a combination was influenced by an aim to contribute toward
the debate as to which nutrient is most effective for various
clinical populations. EPA was chosen in this study because it
is a precursor to the family of eicosanoids that are antagonistic
to families of potent proinflammatory mediators produced from
arachidonic acid. As such, three proinflammatory cytokines were
included as secondary outcomes to explore the nature and
extent that EPA exerts an anti-inflammatory impact during stress,
and thus provide preliminary evidence of the mechanism of
effect.
There are threemajor limitations associated with this rationale
that may have influenced the outcomes. Firstly, DHA has also
recently been shown to be a potent anti-inflammatory precursor
and may have more widespread neuroprotective roles than
EPA (Sinclair et al., 2007; Bradbury, 2011). Recently, DHA
and EPA have, respectively, been found to be precursors for
families of molecules, called resolvins, that actively help to resolve
inflammation; DHA for D-series and EPA for E-series (Qu et al.,
2015). In addition, DHA is precursor for protectin (Protectin
D1) and maresins. The latter are synthesized from DHA in
macrophages to help regulate inflammation (Serhan et al.,
2015). The discovery of these potent pro-resolving compounds
implies a direct, active and localized role for DHA in tissue
homeostasis.
Further, protectin D1 is also known as neuroprotectin
D1 (NPD1) as its effects are largely within the brain. For
instance, DHA supplementation was shown to reverse the age-
related declines in adenosine triphosphate (ATP) production
in isolated mouse brain tissue, an action which corresponded
with increased NPD1 levels (Afshordel et al., 2015). In
cytokine-stressed (i.e., LPS-stimulated) human brain cells, NPD1
was found to reduce amyloid-beta secretion, hence showing
promise to protect against Alzheimer-linked degeneration
(Lukiw et al., 2005; Palacios-Pelaez et al., 2010). Thus, in
addition to its anti-inflammatory and pro-resolving roles, DHA
is also increasingly recognized for its promising neuroprotective
properties.
Given that psychological stress is largely regulated in the
brain, perhaps the low DHA in the current study was a design
limitation. Indeed, in mice subjected to stressful tasks, such
as forced swimming, a DHA-rich diet helped to significantly
reduce multiple stress hormones, including ACTH (by 25%) and
corticosterone (by 20%; Jiang et al., 2015). Further, DHA was
shown to be more effective than EPA at reducing IL-1β and IL-
6, while EPA was more potent at reducing TNF-α (Mullen et al.,
2010).
Secondly, the dosage of both EPA and DHA are low compared
to the equivalent used in animal studies and may have been too
low to have exerted a pronounced effect. We used 2,200mg EPA
+ 44mg DHA per day for 12 weeks, which is a ratio of 83.3%
EPA to 16.6%DHA. This is consistent with another recent RCT in
261 healthy adults that found that 1,000mg EPA + 400mg DHA
per day for 18 weeks did increase membrane levels by 64% but
did not suppresses ex vivo production of C-reactive protein or
proinflammatory cytokines (Muldoon et al., 2016). The authors
similarly speculated that this may be due to low dosage or perhaps
the activation of other anti-inflammatory pathways that were not
included in the study.
Others have demonstrated that in ex vivo and in vitro studies,
the concentration of LPS used to stimulate the proinflammatory
cytokines influences the anti-inflammatory activity of omega-
3 fatty acids; lower LPS concentrations were associated with
a larger anti-inflammatory response by omega-3 fatty acids
(Mullen et al., 2010). The current study used circulating levels
of cytokines, which circumvents this particular methodological
issue. However, capturing naturally occurring cytokines may also
increase inter-individual variability in the data as many factors
may influence naturally occurring proinflammatory cytokine
levels, such as the nature, extent and timing of the exposure to
the stressor.
The dosage of omega-3 fatty acids required to cause a clinical
effect in humans is still largely uncertain. In rats, dosage may
range from 0.4 to 1 g/kg/day of EPA + DHA (Pusceddu et al.,
2015), which would correspond to a dosage range from 28 to
70 g/d in a 70 kg human. The NHMRC recommends an upper
limit of 3,000mg/d (Nutrient Reference Values for Australia
New Zealand, 2005). However, in a large RCT (n = 302) of
older adults in The Netherlands, two different doses were used
(“high” dose: 1,093mg EPA + 847mg DHA, which corresponds
to eating eight portions of fish per week; “low” dose: 226mg
EPA + 176mg DHA, corresponding with one or two fish meals
per week) were given for 26 weeks. There was no change in
the primary outcome, Quality of Life (QOL) scores, for either
dose. This may have been because the “high” dose is still too
low to exert a clinical effect. While it may increase membrane
levels of the fatty acids, it may be at a basic physiological level,
to correct a widespread population dietary imbalance (Meyer,
2011), which may still be too low to be detected by clinical
assessments.
It may also be that the combination of EPA and DHA is
more effective than either fatty acid alone. An animal study that
investigated EPA vs. DHA vs. the combination of EPA + DHA
on in vitro production of proinflammatory cytokines cultured
from rat monocytes found that the combination of EPA + DHA
had the strongest effect, which they attributed to synergistic
actions through multiple pathways (Zhang et al., 2015). In a
study in humans, the combination of 2,710mg EPA/day +
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2,040mg DHA/day for 4 weeks significantly reduced cigarette
smoking and cravings in 48 smokers (Rabinovitz, 2014). The
increase in DHA in that study meant that the participants were
getting double the dose of n-3FAs as those in our study and
the Dutch study. Perhaps future research needs to consider not
only increasing but balancing the dosage of both EPA and DHA
in supplementation to optimize both physiological and clinical
effects.
Finally, the physiological state of psychological stress is not a
stable condition; the organism moves from an acute/emergency
phase of stress into later adaptive phases if exposure is prolonged.
In this study, chronic work stress was used as a model of stress
because it was thought to be relatively stable. While at least one
meta-analysis found that levels of proinflammatory cytokines
are increased during acute psychological stress (Steptoe et al.,
2007), an earlier and broader meta-analysis of more than 300
original studies found that most arms of the immune system are
suppressed during chronic stress (Segerstrom and Miller, 2004).
It would seem that during chronic stress the immune system is
already suppressed through other regulatory mechanisms, thus
there is no requirement to further suppress it. Hence, a regulatory
role of omega-3 fatty acids may be more complex than simply
antagonistic effects toward proinflammatory cytokines. If an
immune system is already chronically suppressed due to stress
mechanisms, it would not seem logical or desirable to further
suppress it; rather, it may be more desirable to stimulate it. If a
cytokine response to stress is not already exaggerated, it may not
be desirable for omega-3 fatty acids to blunt a healthy cellular
response to a stressor. It would seem therefore that there are
multiple mechanisms regulating the proinflammatory cytokines
during chronic stress, and that the role of omega-3 fatty acidsmay
be muchmore regulatory and subtle than this study was designed
to capture.
To further investigate a role for omega-3 fatty acids in stress,
particularly with regards to the inflammatory impact of stress,
future studies could focus on the prevention of an exaggerated
response to an acute stressor, rather than a reduction of chronic
stress. Most of the early stress work was conducted in university
environments in fit and healthy, young, male medical students
using exam stress as a model for stress. However, the ability to
control experimentally for many potential cofactors and thus the
strong internal validity comes at a cost of poor external validity.
The findings from young, healthymales in their primemay not be
generalizable to a general and aging population. More pragmatic
studies in stress in the general population are needed, so the
difficulties of modeling chronic stress will need to be addressed.
Future studies should address the role of DHA in stress, with
particular emphasis on coping mechanisms. Perhaps DHA or a
better balance of EPA and DHA may yet prove to have more of
an impact in stress, resilience and coping. A recent pilot study
reports that 75% of psychiatric patients screened were found to
have <4% EPA + DHA as a proportion to total fatty acid levels
in whole blood, compared with 25% of the general population in
the U.S. (Messamore and McNamara, 2016). A study on a prison
population in Australia found a median EPA + DHA of 4.7%
as a proportion to total fatty acids, indicating that almost half
of all the prisoners had very low cell membrane levels, which
was correlated with increased aggression and attention deficit
disorder (Meyer et al., 2015). Thus, the “omega index” (EPA +
DHA) may be more important than either nutrient in isolation
for obtaining clinically assessable effects. Further work is required
to standardize the omega index (von Schacky, 2014).
Finally, stress is a multidimensional construct, and its
representation as a single global factor does not capture the subtly
differentiated relationships between the various stress factors,
stress biomarkers and the fatty acids. The PSS has been found to
have a three factor structure, with cytokines and fatty acids having
differential relationships with the different factors (Bradbury
et al., 2012; Bradbury, 2013). Future mediation modeling with
this data may find more indirect relationships among the
variables when stress is represented as a multidimensional
construct.
CONCLUSION
This study demonstrated that 2.2 g/day of an EPA-rich fish oil
for 12 weeks did not reduce psychological stress in people with
chronic work stress.
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